GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Psomagen Inc (XKRX:950200) » Definitions » Debt-to-Revenue

Psomagen (XKRX:950200) Debt-to-Revenue : 0.13 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Psomagen Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Psomagen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩1,604 Mil. Psomagen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩3,304 Mil. Psomagen's annualized Revenue for the quarter that ended in Mar. 2024 was ₩37,441 Mil. Psomagen's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.13.


Psomagen Debt-to-Revenue Historical Data

The historical data trend for Psomagen's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psomagen Debt-to-Revenue Chart

Psomagen Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial 1.13 0.41 0.28 0.12 0.16

Psomagen Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.15 0.17 0.15 0.13

Competitive Comparison of Psomagen's Debt-to-Revenue

For the Diagnostics & Research subindustry, Psomagen's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psomagen's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Psomagen's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Psomagen's Debt-to-Revenue falls into.



Psomagen Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Psomagen's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1506.71 + 3482.757) / 32274.664
=0.15

Psomagen's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1603.936 + 3304.398) / 37440.808
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Psomagen Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Psomagen's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Psomagen (XKRX:950200) Business Description

Traded in Other Exchanges
N/A
Address
1330 Piccard Drive, Suite 103, Rockville, MD, USA, 20850
Psomagen Inc, formerly Macrogen Corp provides total genomic solutions for both clinical and research purposes. It is mainly focused on end-to-end sequencing services. The company also offers services such as personal DNA tests, clinical sequencing, research sequencing, and others.

Psomagen (XKRX:950200) Headlines

No Headlines